Lymphoepithelial carcinoma of the salivary gland—A great cytologic mimicker in the head and neck region, and the first report of <scp>SSTR2</scp> expression on cytologic material

Punjabi, Lavisha S; Seow, Min Kai Daryl; Ahmed, Syed Salahuddin

doi:10.1002/dc.25038

Cited by 2 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tracer-uptake in DOTATOC PET/CTs has also been reported in other tumors, such as lymphoepithelial carcinoma, a rare tumor entity with only a few hundred reported cases worldwide [41]. A study found a high concentration and intensity of SSTR2 when examining nine Epstein-Barr virus-positive nasopharyngeal carcinomas using immunohistochemistry [42].…”

Section: Discussionmentioning

confidence: 90%

Novel Discovery of the Somatostatin Receptor (SSTR2) in Pleomorphic Adenomas via Immunohistochemical Analysis of Tumors of the Salivary Glands

Johnson,

Hofauer,

Wirth

et al. 2023

Cancers

View full text Add to dashboard Cite

Reliable preoperative diagnosis between salivary gland tumor entities is difficult. In this monocentric retrospective study, we examined the somatostatin receptor 2 (SSTR2) status of salivary gland tumors after salivary gland tumor resection via immunohistochemistry (IHC), and stains were compared in analogy to the HER2 mamma scale. A total of 42.3% of all pleomorphic adenoma (PA) tumors (42 of 99, 95% confidence interval 32.5–52.8%) demonstrated ≥20% of cells displaying the SSTR2 as compared to just 1% of all other tumors (1/160, 95% CI 0.02–3.4%). The other tumor was a neuroendocrine carcinoma. PA had a higher intensity of SSTR2 staining, with 90.9% staining ≥ an intensity of 2 (moderate). Tumors with an intensity of SSTR2 expression equal to or greater than 2 had an 89.9% likelihood of being a PA (95% CI: 82.2–95.0%, AUC: 0.928). Only one Warthin tumor demonstrated a ‘strong’ SSTR2 staining intensity. No Warthin tumor showed a percentage of cells staining for SSTR2 above ≥20%. This result demonstrates consistent and strong expression of SSTR2 in PAs as compared to Warthin tumors, which may allow physicians to utilize radioligand-somatostatin analog PET CT/MR imaging to diagnose the PA. SSTR2 positivity, if shown to be clinically relevant, may allow peptide receptor radionuclide therapy in the future.

show abstract

Section: Discussionmentioning

confidence: 90%

Novel Discovery of the Somatostatin Receptor (SSTR2) in Pleomorphic Adenomas via Immunohistochemical Analysis of Tumors of the Salivary Glands

Johnson,

Hofauer,

Wirth

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…Hence, we decided to recruit this patient into an ongoing study on somatostatin receptor imaging in EBV related cancers (NCT05581550). We performed further immunohistochemistry on the initial specimen from her primary tumor, and it was positive for SSTR2 7,8 . 68 Ga-DOTATATE PET/CT ( A ) revealed multiple new DOTATATE-avid mediastinal, internal mammary, bilateral interlobar, superior diaphragmatic, and intercostal nodal metastases ( B ), as well as multiple new non to mildly DOTATATE-avid bilateral pulmonary ( C ) and right pleural metastases ( D ).…”

mentioning

confidence: 99%

68Ga-DOTATATE PET/CT of Metastatic Lymphoepithelial Carcinoma of Parotid Gland

Low,

Loke,

Wang

et al. 2023

Clin Nucl Med

View full text Add to dashboard Cite

We present a case of a 59-year-old woman with lymphoepithelial carcinoma of left parotid gland. She was treated with radical radiotherapy, but her plasma Epstein-Barr virus DNA load continued to increase despite good locoregional response. As her primary tumor was positive for somatostatin receptor type 2, we performed 68Ga-DOTATATE PET/CT, which revealed multiple DOTATATE-avid distant metastases.

show abstract

Lymphoepithelial carcinoma of the salivary gland—A great cytologic mimicker in the head and neck region, and the first report of SSTR2 expression on cytologic material

Cited by 2 publications

References 12 publications

Novel Discovery of the Somatostatin Receptor (SSTR2) in Pleomorphic Adenomas via Immunohistochemical Analysis of Tumors of the Salivary Glands

Novel Discovery of the Somatostatin Receptor (SSTR2) in Pleomorphic Adenomas via Immunohistochemical Analysis of Tumors of the Salivary Glands

68Ga-DOTATATE PET/CT of Metastatic Lymphoepithelial Carcinoma of Parotid Gland

Contact Info

Product

Resources

About